Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake.
OBJECTIVE
To evaluate the cognitive reserve hypothesis by examining whether individuals of greater educational attainment have better cognitive function than individuals with less education in the presence of elevated fibrillar brain amyloid levels.


METHODS
Uptake of carbon 11-labeled Pittsburgh Compound B ([(11)C]PiB) was measured for participants assessed between August 15, 2003, and January 8, 2008, at the Washington University Alzheimer's Disease Research Center and diagnosed either as nondemented (n = 161) or with dementia of the Alzheimer type (n = 37). Multiple regression was used to determine whether [(11)C]PiB uptake interacted with level of educational attainment to predict cognitive function.


METHODS
Scores on the Clinical Dementia Rating sum of boxes, Mini-Mental State Examination, and Short Blessed Test and individual measures from a psychometric battery.


RESULTS
Uptake of [(11)C]PiB interacted with years of education in predicting scores on the Clinical Dementia Rating sum of boxes (P = .003), the Mini-Mental State Examination (P < .001), the Short Blessed Test (P = .03), and a measure of verbal abstract reasoning and conceptualization (P = .02) such that performance on these measures increased with increasing education for participants with elevated PiB uptake. Education was unrelated to global cognitive functioning scores among those with lower PiB uptake.


CONCLUSIONS
The results support the hypothesis that cognitive reserve influences the association between Alzheimer disease pathological burden and cognition.
Roe
Catherine M
CM
Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO 63110, USA. cathyr@wustl.edu
Mintun
Mark A
MA
D'Angelo
Gina
G
Xiong
Chengjie
C
Grant
Elizabeth A
EA
Morris
John C
JC
D000368:Aged; D000544:Alzheimer Disease / Q000175:diagnosis* / Q000378:metabolism / Q000523:psychology*; D000682:Amyloid / Q000378:metabolism; D000814:Aniline Compounds / Q000493:pharmacokinetics*; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism; D002250:Carbon Radioisotopes / Q000493:pharmacokinetics; D003071:Cognition; D004522:Educational Status; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008960:Models, Psychological; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D011569:Psychiatric Status Rating Scales; D011581:Psychological Tests; D013844:Thiazoles / Q000493:pharmacokinetics*
C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000682:Amyloid; D000814:Aniline Compounds; D002250:Carbon Radioisotopes; D013844:Thiazoles